RE: Speaking of Research19 Dec 2021 16:20
I see kkrriiss has cross-pollinated my post to the 'other place', 22 up-votes, whilst selectively removing the last paragraph expressing concerns about the ability of Tern to finance its portfolio companies. A post from there seems equally relevant given stated concerns as to how cheap the Venafi buy in was,
"Venafi might have seemed cheap but you lot seem to be missing the constraints placed on the deal by available funding from Tern, Alsop Louie and SamenUK. That comprised their cash in hand, the loan notes and the desire to maintain a majority holding in Device Authority by Tern. Without coming back to the markets for a further fund raise that capped the amount Tern was able to invest and similarly capped the amount Venafi was permitted to invest. It is also likely that it constrained the perceived overall valuation of the company."
Here's a good idea kkrriiss. Next time you quote me do so in full otherwise I and others will get the impression you are not a trustworthy source.